within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB08_Pirarubicin;
model Pirarubicin 
   extends Pharmacolibrary.Drugs.ATC.L.L01DB08;

  annotation(Documentation(
    info ="<html><body><p>Pirarubicin is an anthracycline antineoplastic agent structurally related to doxorubicin, primarily used for the treatment of various cancers, including breast, bladder, and lung cancers. It is typically administered intravenously or via intravesical instillation. Pirarubicin is approved in certain countries, such as Japan, but is not globally approved.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (various types), after intravenous infusion.</p><h4>References</h4><ol><li><p>Nagasawa, K, et al., &amp; Nakamura, H (1991). Pharmacokinetics of pirarubicin in pediatric patients. <i>Journal of pharmacobio-dynamics</i> 14(4) 222–230. DOI:<a href=&quot;https://doi.org/10.1248/bpb1978.14.222&quot;>10.1248/bpb1978.14.222</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1941503/&quot;>https://pubmed.ncbi.nlm.nih.gov/1941503</a></p></li><li><p>Cong, W, et al., &amp; Luo, G (2010). Characterization and pharmacokinetics of a novel pirarubicin liposome powder. <i>Drug development and industrial pharmacy</i> 36(10) 1186–1194. DOI:<a href=&quot;https://doi.org/10.3109/03639041003695097&quot;>10.3109/03639041003695097</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20515395/&quot;>https://pubmed.ncbi.nlm.nih.gov/20515395</a></p></li><li><p>Kawano, K, et al., &amp; Maitani, Y (2003). Preparation and pharmacokinetics of pirarubicin loaded dehydration-rehydration vesicles. <i>International journal of pharmaceutics</i> 252(1-2) 73–79. DOI:<a href=&quot;https://doi.org/10.1016/s0378-5173(02)00628-2&quot;>10.1016/s0378-5173(02)00628-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12550782/&quot;>https://pubmed.ncbi.nlm.nih.gov/12550782</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Pirarubicin;
